Nalls Sherbakoff Group’s Ligand Pharmaceuticals LGND Stock Holding History

Nalls Sherbakoff Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$0	Buy	+3	New	+$320	﹤0.01%	396

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Nalls Sherbakoff Group's LGND Position: Q4 2018 in Review

Nalls Sherbakoff Group opened a new position in Ligand Pharmaceuticals (LGND) in Q4 2018: 3 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #396 among its holdings.

362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

Nalls Sherbakoff Group held 3 shares of Ligand Pharmaceuticals worth $0 as of Q4 2018.
Ligand Pharmaceuticals was a new Nalls Sherbakoff Group position in Q4 2018.
Ligand Pharmaceuticals made up ﹤0.01% of Nalls Sherbakoff Group's portfolio in Q4 2018, its #396 holding.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Nalls Sherbakoff Group's 13F filing for Q4 2018, filed 13 Feb 2019.